Literature DB >> 11309820

Detection of MRP functional activity: calcein AM but not BCECF AM as a Multidrug Resistance-related Protein (MRP1) substrate.

D P Olson1, B J Taylor, S P Ivy.   

Abstract

Resistance to anticancer drugs has been attributed to an array of cellular changes. The multidrug resistance-related protein (MRP1) is an efflux pump whose overexpression confers resistance to several classes of drugs, such as the anthracyclines, epipodophyllotoxins, and vinca alkaloids. These drugs are mainstays in cancer therapy. MRP1 overexpression is hypothesized to be a causative agent of clinical treatment failure. Consistently accurate methods for detecting this protein are necessary to further understand its biology and delineate its possible clinical relevance. Flow cytometric analysis of multidrug resistance (MDR) is a valuable method to evaluate both antigen expression and function. Using flow cytometry, we assayed MRP1 functional activity in pediatric leukemic blasts and an array of MDR+ and WT cell lines. We conclude that calcein AM, when used in a retention assay with MRP1-specific modulators, is able to reliably detect MRP functional activity. 2'-7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF AM) transport is not indicative of MRP1 overexpression. .

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309820     DOI: 10.1002/cyto.1072

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  16 in total

1.  Multidrug resistance transporters in the olfactory receptor neurons of Xenopus laevis tadpoles.

Authors:  Ivan Manzini; Detlev Schild
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

2.  Efflux Transporters Regulate Arsenite-Induced Genotoxicity in Double Negative and Double Positive T Cells.

Authors:  Huan Xu; Sebastian Medina; Fredine T Lauer; Christelle Douillet; Ke Jian Liu; Laurie G Hudson; Miroslav Stýblo; Lauren M Aleksunes; Scott W Burchiel
Journal:  Toxicol Sci       Date:  2017-07-01       Impact factor: 4.849

3.  Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.

Authors:  Tapan K Dash; V Badireenath Konkimalla
Journal:  Pharm Res       Date:  2017-05-23       Impact factor: 4.200

4.  Experimental and computational studies of epithelial transport of mefenamic acid ester prodrugs.

Authors:  Kamonthip Wiwattanawongsa; Vimon Tantishaiyakul; Luelak Lomlim; Yon Rojanasakul; Sirirat Pinsuwan; Sanae Keawnopparat
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

5.  Spatiotemporally controlled single cell sonoporation.

Authors:  Zhenzhen Fan; Haiyan Liu; Michael Mayer; Cheri X Deng
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

6.  Assessment of multidrug resistance on cell coculture patterns using scanning electrochemical microscopy.

Authors:  Sabine Kuss; David Polcari; Matthias Geissler; Daniel Brassard; Janine Mauzeroll
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-17       Impact factor: 11.205

7.  Assessment of drug transporter function using fluorescent cell imaging.

Authors:  Kristin M Bircsak; Christopher J Gibson; Robert W Robey; Lauren M Aleksunes
Journal:  Curr Protoc Toxicol       Date:  2013-09-23

8.  The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins.

Authors:  Carlos Luna-Tortós; Bernhard Rambeck; Uwe H Jürgens; Wolfgang Löscher
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

9.  Nrf2 Regulates the Sensitivity of Mouse Keratinocytes to Nitrogen Mustard via Multidrug Resistance-Associated Protein 1 (Mrp1).

Authors:  Ronald G Udasin; Xia Wen; Kristin M Bircsak; Lauren M Aleksunes; Michael P Shakarjian; Ah-Ng Tony Kong; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Toxicol Sci       Date:  2015-10-09       Impact factor: 4.849

10.  P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.

Authors:  Martin Grundy; Claire Seedhouse; Nigel H Russell; Monica Pallis
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.